2162.HK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (16 Apr 2024 @ 04:08):

Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases...

Stats
Today's Volume	924 500
Average Volume	2.03M
Market Cap	8.34B
EPS	HKD0 ( 2024-03-25 )
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-20.37
ATR14	HKD0.0730 (0.24%)

Volume Correlation

Long: 0.10 (neutral)

Short: 0.12 (neutral)

Signal:(49.976) Neutral

Keymed Biosciences Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Keymed Biosciences Inc. Correlation - Currency/Commodity

-0.51
( weak negative )

-0.66
( moderate negative )

0.00
( neutral )

-0.41
( neutral )

-0.79
( moderate negative )

0.42
( neutral )

Keymed Biosciences Inc. Financials

Annual	2022
Revenue:	HKD100.06M
Gross Profit:	HKD97.48M (97.42 %)
EPS:	HKD-1.180

Q2	2023
Revenue:	HKD163.56M
Gross Profit:	HKD156.05M (95.41 %)
EPS:	HKD0.0899

Q1	2023
Revenue:	HKD163.56M
Gross Profit:	HKD156.05M (95.41 %)
EPS:	HKD0.0899

Q4	2022
Revenue:	HKD31 500.00
Gross Profit:	HKD7 500.00 (23.81 %)
EPS:	HKD-0.600

Financial Reports:

No articles found.

Keymed Biosciences Inc.

Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company is also developing CM326, a monoclonal antibody targeting thymic stromal lymphopoietin to treat moderate-to severe AD, CRSwNP, asthma, and COPD. In addition, it develops CMG901 for the treatment of solid tumors, and gastric and gastroesophageal cancers; and CM313, a humanized monoclonal antibody to treat relapsed or refractory multiple myeloma, lymphoma and other hematological malignancies, and systemic lupus erythematosus. Further, the company is developing MIL95/CM312, a humanized monoclonal antibody targeting CD47; CM338, an antagonist antibody against mannose-binding lectinassociated serine protease-2; CM355 for the treatment of relapsed or refractory non-Hodgkin's lymphoma; CM336 to treat multiple myeloma; CM350 for the treatment of solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody. Keymed Biosciences Inc. was formerly known as 2Health Biosciences, Inc. The company was founded in 2016 and is headquartered in Chengdu, the People's Republic of China.